Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma

NCT02550678 is registered in ClinicalTrials.gov with Ascend Biopharmaceuticals Ltd as lead sponsor.

NCT NCT02550678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02550678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma
Lead sponsor
Ascend Biopharmaceuticals Ltd
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2015
Completion date
November 30, 2017
Enrollment
16 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell nevus syndrome, nodular basal cell carcinoma of skin, skin neoplasm